For the fourth quarter of 2015, Boston Scientific’s sales hit $1.978 billion, representing a 10 percent jump in operational revenue compared with the same time period the previous year, while its adjusted earnings per share increased from $0.22 to $0.26.
The company’s operational revenue growth in the fourth quarter increased 23 percent in the MedSurg division and 7 percent in the Cardiovascular division. Meanwhile, sales were flat in the Rhythm Management division.
For 2015 as a whole, the company’s sales increased eight percent to $7.477 billion and its adjusted earnings per share increased from $0.84 to $0.93.
During the fourth quarter, Boston Scientific launched the Synergy stent system in the U.S. and Japan. The Synergy is the first FDA-approved bioabsorbable polymer drug-eluting stent system.
On Nov. 10, Boston Scientific announced that it had agreed to acquire the interventional radiology portfolio of CeloNova Biosciences. Later that month, the FDA approved the company’s AngioJet ZelanteDVT thrombectomy catheter to treat patients with deep vein thrombosis.
Boston Scientific also provided guidance for 2016. The company estimated that revenue would be between $7.9 billion to $8.1 billion, which would represent a 7 percent to 10 percent revenue growth on an operational basis. It also estimated GAAP income of $0.62 to $0.67 per share.